Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-002 in Advanced Cancer
NCT05276310Phase 1Recruiting
- Sponsor
- ImmuneOncia Therapeutics, Inc.
- Start
- Jun 2022
- Primary completion
- Dec 2027
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of IMC-002 in cancer, hepatocellular carcinoma (HCC), triple-negative breast cancer (TNBC) and 3 more, sponsored by ImmuneOncia Therapeutics, Inc. Primary endpoints: Dose-Limiting Toxicities at 21 days and Treatment-Emergent Adverse Events at 1 year. Started Jun 2022; status: recruiting.
02
Drugs
IMC-002
03
Conditions
cancerhepatocellular carcinoma (HCC)triple-negative breast cancer (TNBC)biliary tract cancer (BTC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05276310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05276310.